Hodgkin Lymphoma

• CLINICAL_TRIALS trial_result · 2023-06-09
  Clinical Trial Update: High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant [Phase 2]

  Phase 2 clinical trial evaluating high-dose cyclophosphamide, tacrolimus, and mycophenolate mofetil to prevent graft-versus-host disease in …

• CLINICAL_TRIALS trial_result · 2023-06-09
  Clinical Trial Update: Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk [Phase 2]

  Phase 2 trial evaluating nivolumab as maintenance therapy after autologous stem cell transplant in Hodgkin lymphoma patients at relapse/prog…

• CLINICAL_TRIALS trial_result · 2023-06-02
  Clinical Trial Update: Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 2]

  Phase 2 trial evaluating pembrolizumab in combination with chemotherapy for relapsed or refractory Hodgkin lymphoma; status and results are …

• CLINICAL_TRIALS trial_result · 2023-05-31
  Clinical Trial Update: Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma [Phase 3]

  Phase 3 trial evaluating brentuximab vedotin combined with chemotherapy in children and young adults with advanced Hodgkin lymphoma (stages …

• CLINICAL_TRIALS trial_result · 2023-05-31
  Clinical Trial Update: Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma [Phase 3]

  Phase 3 trial evaluating brentuximab vedotin in combination chemotherapy for pediatric and young adult Hodgkin lymphoma across advanced-stag…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2023-05-03
  Clinical Trial Update: Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma [Phase 2]

  Phase 2 trial investigating umbralisib and pembrolizumab in relapsed or refractory classical Hodgkin lymphoma was terminated with results po…

• CLINICAL_TRIALS trial_result · 2023-04-27
  Clinical Trial Update: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) [Phase 2]

  This Phase 2 pediatric MATCH trial update reports results for tazemetostat in patients with relapsed or refractory solid tumors, non-Hodgkin…

• CLINICAL_TRIALS trial_result · 2023-04-27
  Clinical Trial Update: Reduced Intensity Conditioning Transplant Using Haploidentical Donors [Phase 2]

  Phase 2 clinical trial investigating reduced intensity conditioning transplant using haploidentical donors for various hematologic malignanc…

• CLINICAL_TRIALS trial_result · 2023-04-18
  Clinical Trial Update: Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma [Phase 4]

  Phase 4 clinical trial investigating pentoxifylline to enhance tumor cell death in Hodgkin lymphoma.

• CLINICAL_TRIALS trial_result · 2023-04-12
  Clinical Trial Update: A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma [Phase 1, Phase 2]

  A phase 1/2 clinical trial evaluating safety and efficacy of a PET-adapted fixed-dose nivolumab regimen with ifosfamide, carboplatin, and et…

• CLINICAL_TRIALS trial_result · 2023-04-05
  Clinical Trial Update: Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) [Phase 2]

  Phase 2 trial update for autologous CD30.CAR-T cells in relapsed/refractory Hodgkin lymphoma (CHARIOT) is ongoing (Phase 2, active not recru…

• CLINICAL_TRIALS trial_result · 2023-01-23
  Clinical Trial Update: Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis [Phase 2]

  Phase 2 trial of adoptive immunotherapy in relapsed hematological malignancies with early GVHD prophylaxis has completed enrollment and post…

• CLINICAL_TRIALS trial_result · 2023-01-20
  Clinical Trial Update: Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant [Phase 2]

  Phase 2 trial evaluating ibrutinib in patients with refractory or relapsed lymphoma after donor stem cell transplant completed; results post…

• CLINICAL_TRIALS trial_result · 2023-01-10
  Clinical Trial Update: Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas [Phase 1, Phase 2]

  Phase 1/2 trial evaluating nivolumab with or without ipilimumab in younger patients with recurrent or refractory solid tumors or sarcomas; c…

• CLINICAL_TRIALS trial_result · 2023-01-04
  Clinical Trial Update: Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient [Phase 1, Phase 2]

  Phase 1/2 trial update evaluating the combination of Adcetris and Levact for Hodgkin lymphoma in older patients; study completed.

• CLINICAL_TRIALS trial_result · 2022-12-21
  Clinical Trial Update: Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab, Bendamustine, Gemcitabine, Vinorelbine (Nivo-BeGEV) in Patients With Relapsed/Refractory Hodgkin Lymphoma [Phase 2]

  A Phase 2 multicenter trial evaluating PET-adapted Nivolumab, Bendamustine, Gemcitabine, Vinorelbine in relapsed/refractory Hodgkin lymphoma…

• CLINICAL_TRIALS trial_result · 2022-12-08
  Clinical Trial Update: Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL [Phase 2]

  Phase 2 trial results for pembrolizumab after autologous stem cell transplant in Hodgkin lymphoma, diffuse large B-cell lymphoma, and periph…

• CLINICAL_TRIALS trial_result · 2022-12-08
  Clinical Trial Update: Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. [Phase 2]

  Phase 2 trial update on conditioning regimens for transplantation of unrelated donor umbilical cord blood in patients with hematologic malig…

• CLINICAL_TRIALS trial_result · 2022-11-23
  Clinical Trial Update: Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies [Phase 1, Phase 2]

  Phase 1/2 trial update on pralatrexate plus romidepsin in relapsed/refractory lymphoid malignancies and multiple myeloma.

• CLINICAL_TRIALS trial_result · 2022-10-31
  Clinical Trial Update: A Study of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma [Phase 2]

  Phase 2 clinical trial update for CS1001 in relapsed or refractory classical Hodgkin lymphoma has completed.

• CLINICAL_TRIALS trial_result · 2022-10-27
  Clinical Trial Update: Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients [Phase 1, Phase 2]

  A clinical trial update evaluating immunotherapy after reduced-intensity conditioning and allogeneic stem cell transplant for poor risk CD30…

• CLINICAL_TRIALS trial_result · 2022-10-06
  Clinical Trial Update: Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas [Phase 2]

  Phase II trial evaluating alemtuzumab with DA-EPOCH-R in relapsed or refractory Hodgkin lymphoma and diffuse large B-cell lymphoma has compl…

• CLINICAL_TRIALS trial_result · 2022-08-19
  Clinical Trial Update: Study Of Nivolumab Alone, Or In Combination With Vinblastin In Patients With Classical Hodgkin Lymphoma [Phase 2]

  Phase 2 clinical trial evaluating nivolumab alone or with vinblastine in classical Hodgkin lymphoma has completed.

• CLINICAL_TRIALS trial_result · 2022-08-19
  Clinical Trial Update: Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. [Phase 2]

  A Phase 2 trial evaluating brentuximab vedotin in combination with chemotherapy for untreated Hodgkin lymphoma has completed.

• CLINICAL_TRIALS trial_result · 2022-05-12
  Clinical Trial Update: Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma [Phase 1, Phase 2]

  Phase 1/2 trial evaluating mocetinostat plus brentuximab vedotin in relapsed or refractory Hodgkin lymphoma has completed with results poste…